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Abstract
Commensal gastrointestinal bacteria resist the expansion of pathogens and are lost during
critical illness, facilitating pathogen colonization and infection. We performed a prospective,
ICU-based study to determine risk factors for loss of gut colonization resistance during the
initial period of critical illness. Rectal swabs were taken from adult ICU patients within 4
hours of admission and 72 hours later, and analyzed using 16S rRNA gene sequencing and
selective culture for vancomycin-resistant Enterococcus (VRE). Microbiome data was visu-
alized using principal coordinate analyses (PCoA) and assessed using a linear discriminant
analysis algorithm and logistic regression modeling. 93 ICU patients were analyzed. At 72
hours following ICU admission, there was a significant decrease in the proportion of Clostrid-
ial Clusters IV/XIVa, taxa that produce short chain fatty acids (SCFAs). At the same time,
there was a significant expansion in Enterococcus. Decreases in Cluster IV/XIVa Clostridia
were associated with loss of gut microbiome colonization resistance (reduced diversity and
community stability over time). In multivariable analysis, both decreased Cluster IV/XIVa
Clostridia and increased Enterococcus after 72 hours were associated with receipt of antibi-
otics. Cluster IV/XIVa Clostridia, although a small fraction of the overall gastrointestinal
microbiome, drove distinct clustering on PCoA. During initial treatment for critical illness,
there was a loss of Cluster IV/XIVa Clostridia within the distal gut microbiome which associ-
ated with an expansion of VRE and with a loss of gut microbiome colonization resistance.
Receipt of broad-spectrum antibiotics was associated with these changes.
Introduction
The gastrointestinal microbiome plays crucial roles in maintenance of the gut mucosal barrier,
immunity, and protection against infection [1]. In patients who are critically ill, the normal
gut microbiome substantially shifts, likely impacted both from critical illness itself and from
antibiotics and other exposures common to the intensive care unit (ICU) [2].
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Loss of colonization resistance, the ability of the normal gut microbiome to resist the expan-
sion of pathogens, is thought to be a risk factor for ICU-acquired infections and may contrib-
ute to the organ dysfunction seen during sepsis [3, 4]. Typical hospital pathogens such as
Gram-negative bacilli and vancomycin-resistant Enterococcus (VRE) are more prevalent in
ICU patients compared to healthy individuals [5]. Fecal microbial diversity, a proxy measure
for colonization resistance, is low at the time of ICU admission [6] and further declines with
treatment; prolonged critical illness and the accompanying antibiotics may lead to a state of
ultra-low diversity and near-complete loss of colonization resistance [7]. In bone marrow
transplant (BMT) patients, loss of fecal microbial diversity is followed by domination with
enteric pathogens including VRE and increased risk for subsequent infection [8, 9].
The specific changes that lead to loss of normal colonization resistance are uncertain. Loss
of obligate anaerobes may facilitate the acquisition of pathogens and has been observed as a
consequence of antibiotics [10–12]. In particular, loss of Clostridial Clusters IV/XIVa, which
produce butyrate and other short chain fatty acids (SCFA), has been correlated with suscepti-
bility to enteric pathogens [13]. In small ICU-based studies, loss of anaerobes has been associ-
ated with increases in Enterococcus and Staphylococcus [14]. Large shifts away from anaerobic
commensals have been seen in the ICU and have been associated with worse clinical outcomes
[15, 16]. However, it is unknown exactly which bacteria or combination of bacteria are lost,
when, and how they may maintain colonization resistance.
We conducted this study to determine the key fecal microbial changes during the period
immediately following ICU admission. Our goal was to identify potentially protective bacterial
taxa that might be lost during this initial ICU treatment period, and to test which clinical fac-
tors were associated with these changes.
Materials and methods
Patient population
Adults18 years old were considered for the study if they were newly admitted to any one of
5 distinct medical or surgical ICUs and could be reached within 4 hours of ICU admission.
Patients were excluded for prior Clostridium difficile infection (within 90 days), bacterial
bloodstream infections (within 30 days), or ICU admissions (within 30 days). Patients were
also excluded if both study assessments could not be completed due to death, discharge, or
patient refusal. Informed consent was obtained from all subjects or from appropriate surro-
gates when subjects lacked capacity. Default consent was written although verbal (telephone)
consent was accepted when subjects lacked capacity and the appropriate surrogate was not
available in person. This study was approved by the institutional review board of Columbia
University.
Study design
This was a prospective, ICU-based study consisting of two assessments. The initial study
assessment was made within 4 hours of ICU admission and the second and final study assess-
ment was performed 72 hours later (+/- 4 hours).
Study assessments
At each study assessment, samples were taken and information was gathered. Two duplicate
deep rectal flocked nylon swabs [17] (Copan Diagnostics, Murrieta, CA) were collected and
the following information was gathered at the bedside: vital signs, use of life support devices
(e.g., mechanical ventilation, hemodialysis), and the Glasgow Coma Scale [18]. Demographic
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information, laboratory data, and data related to interventions performed in the ICU between
study visits was extracted from the electronic medical record. For laboratory data, test results
were used from the first venous blood draw in the ICU (corresponding to the first study assess-
ment) and from a venous blood draw either at or immediately preceding the 72 hour mark
(corresponding to the second study assessment). ICU interventions were recorded including
antibiotics (any dose or duration), proton pump inhibitors, mechanical ventilation, hemodial-
ysis (either intermittent or continuous), and enteral feeding (by mouth or by naso-enteric
tube). Clinical and laboratory data were used to estimate acute severity of illness (APACHE
IV) [19].
16S rRNA gene sequencing
The first of each pair of duplicate swabs was frozen at -80˚C for batched DNA extraction at the
end of the study (PowerFecal, MoBio, Carlsbad, CA). Polymerase chain reaction was per-
formed targeting the V4 hypervariable region of the 16S ribosomal RNA gene with primers
derived from the human microbiome project (primers and protocol in Supplementary materi-
als and methods) [20–22]. After PCR of V4 hypervariable region with above primers/protocol,
samples were pooled and purified with the QIAquick PCR kit (Qiagen, Valencia, CA) and
library quantification performed using a KAPA Library Quantification Kit (Kapa Biosystems,
Wilmington, MA). Sequencing of the 16S ribosomal RNA gene V4 region was performed
using the Illumina HiSeq 4000 platform (Illumina, San Diego, CA).
Singleton reads were discarded and read pairs were merged, trimmed, and filtered for qual-
ity using mothur [23]. Subsequently singleton contigs were discarded. Greengenes [24] was
used as a reference database with additional sequences of interest retrieved from the National
Center for Biotechnology as needed. Clustering of taxonomic units was made at 97% sequence
similarity using USEARCH [25] and taxonomic assignments were made using mothur [23].
FastTree2 [26] was used to generate a phylogenetic tree of the contigs.
The QIIME pipeline [27] was used to calculate α-diversity metrics (Shannon diversity
index and number of observed Operational Taxonomic Units (OTUs)) and β-diversity
(unweighted UniFrac distances [28]), and to generate principal coordinate analysis (PCoA)
plots based on unweighted UniFrac distances. For α- and β-diversity metrics, samples were
rarefied to 50,000 to allow for calculations based on even number of sequences per sample.
Microbiome stability was calculated as the within-individual unweighted UniFrac distance
from ICU admission to 72 hours later where larger UniFrac distances represented greater sam-
ple divergence over time and thus less stability. Sequencing data from the study is available in
the short read archive section of the National Center for Biotechnology Information (accession
number SRP149563).
VRE-selective stool culture
At both study assessments, duplicate rectal swabs were performed and were inoculated into
soy broth with 20% glycerol media at the bedside. After gentle mixing, these swabs were plated
on VRE-selective chromogenic media (Remel, Lenexa KS) and incubated aerobically at 33–
37˚C. After 24 hours, colonies were inspected for characteristics, morphology, and color.
Results were classified categorically according to the manufacturer’s instructions as VRE pres-
ent (including E. faecalis or E. faecium) versus VRE absent.
Statistical approach
Comparisons of clinical data were performed using chi-squared tests, Fisher’s exact test (when
expected cell counts were5), or paired t tests for continuous variables.
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Analysis of gut microbiome data was performed using a stepwise approach. First, an untar-
geted hierarchical linear discriminant analysis (LDA) effect size algorithm (LEfSe) [29] was
used to identify significant within-individual changes, comparing the time of ICU admission
versus 72 hours later. LEfSe tests for non-parametric differences in features (Kruskal-Wallis)
and uses these results for paired testing for a difference between pre-specified classes (Wil-
coxon rank-sum). A LDA cut-off of 2.0 was applied and all taxa were specified at the lowest
possible hierarchical level. LEfSe can exaggerate the importance of scarce taxa, so this analysis
was limited to taxa that had both significantly changed and that had a relative abundance
0.005 in any sample. Second, the univariable relationships between clinical data and taxa
identified as significantly changed by LEfSe were examined. For this analysis, LEfSe taxa were
divided into quartiles based on relative abundance after 72 hours. Third, a multivariable model
was constructed for these relationships using ordered logistic regression. Variables considered
for this model had an unadjusted relationship with LEfSe taxa at the p<0.10 level. To further
explore the data, sensitivity analyses were performed testing for relationships between dynamic
clinical changes and altered LEfSe taxa within the final model (e.g., worsening APACHE IV).
Post hoc clustering analyses were performed selecting cut-offs based on the observed data.
To test for differences in α-diversity, the Wilcoxon U test and was used with GraphPad Prism
7 (La Jolla, CA). To test for differences in β-diversity, unweighted UniFrac distances were used
with QIIME after a Bonferroni-adjusted Monte Carlo simulation [27]. STATA 14 (StataCorp,
College Station, TX) was used for multivariable modeling and other significance testing. All
tests were performed 2-sided at the alpha 0.05 level.
Results
Clinical characteristics
A total of 192 patients were approached to enroll 109 subjects including 93 who completed
both study assessments and were analyzed (16 subjects died or refused the second assessment).
For two subjects, there were <1,000 16S reads obtained from the swabs performed at ICU
admission and these samples were excluded; the median sequence depth per sample for the
remaining 184 samples exceeded 1,000,000.
Many subjects had evidence of hemodynamic instability at the time of ICU admission and
most had anemia, leukocytosis, or renal insufficiency (S1 Table). Most patients were clinically
improving during treatment in the ICU with a median decline of 12 points in the APACHE IV
score (p<0.01) representing decreased severity of illness. However, over the 72 hours following
ICU admission, patients were also significantly more likely to develop new fever, anemia, or
hypoalbuminemia (S1 Table). During this initial 72 hour period, 77% of subjects received
broad-spectrum antibiotics including 25% who received vancomycin (Table 1).
Within-individual changes in the gut microbiome
Over 72 hours, there was a modest within-individual decline in fecal microbial diversity that
was not statistically significant (Shannon index, median change -3.5%, p = 0.06) and a signifi-
cant decline in fecal microbial richness (operational taxonomic units, median change -7.1%,
p<0.01). There were no major phylum-level shifts (S1 Fig). LEfSe was used to assess for
within-individual changes in specific bacterial taxa over these initial 72 hours. There was a sig-
nificant decline in the Clostridial Clusters IV (Faecalibacterium prausnitzii) and XIVa (Blautia,
Coprococcus, Roseburia, and Ruminococcus) with an expansion in Enterococcus (Fig 1A–1C;
complete LDA results in S2 Table). Among these Clostridia, the greatest decline was seen in F.
prausnitzii which had an 8-fold median decline over 72 hours (Fig 1C).
Loss of Clostridial Clusters IV and XIVa in the ICU
PLOS ONE | https://doi.org/10.1371/journal.pone.0200322 August 1, 2018 4 / 16
Altered Cluster IV/XIVa Clostridia
To understand the role of taxa found to be significantly altered in the ICU, the Cluster IV/
XIVa Clostridia identified by LEfSe were pooled and organized into quartiles based on relative
abundance, from lowest to highest. Median relative abundance was 2.6% at ICU admission
versus 0.30% 72 hours later (sign-rank p = 0.01, see S2 Fig). On PCoA, there was clustering of
subjects based on levels of Cluster IV/XIVa Clostridia both at the time of ICU admission (Fig
2A) and 72 hours later (Fig 2B) mirroring overall differences in microbial composition. Sev-
enty-two hours after admission, lower levels of Cluster IV/XIVa Clostridia were associated
with decreased diversity (Fig 3A).
Additionally, low levels of Cluster IV/XIVa Clostridia at 72 hours were associated with
decreased within-individual community stability between ICU admission and 72 hours later
as measured by unweighted UniFrac distance (Fig 3B).
Relationship between Enterococcus and Cluster IV/XIVa Clostridia
Enterococcus, which was found to be significantly increased on LEfSe analysis (Fig 1A–1C),
was organized into quartiles. Median relative abundance of Enterococcus was 0.0038% at ICU
admission and 0.067% 72 hours later (sign-rank p<0.01, see S2 Fig). Higher levels of Entero-
coccus at 72 hours were associated with decreased diversity (Fig 4). There was evidence of a
reciprocal relationship where high levels of Enterococcus were only observed with low levels of
Cluster IV/XIVa Clostridia (S3A Fig) and PCoA showed distinct clusters based on high levels
of Cluster IV/XIVa Clostridia or high levels of Enterococcus, without overlap between clusters
(S3B Fig). 16S rRNA gene sequencing results do not distinguish between vancomycin-sensitive
versus vancomycin-resistant Enterococcus (VRE), so VRE culture was performed to assess the
potential clinical importance of Enterococcus from 16S rRNA gene sequencing data. The
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relative abundance of Enterococcus based on 16S rRNA gene sequencing was highly associated
with VRE culture positivity (p<0.01, S4 Fig). There were 23 patients (25%) who received van-
comycin during the initial 72 hours of ICU treatment and among these patients, VRE rates in
culture after 72 hours were 22% compared to 7% for subjects who did not receive vancomycin
(Fisher’s p = 0.11) Enterococcus relative abundance after 72 hours was over 6-fold higher in
subjects who received vancomycin compared to those who did not (rank-sum p = 0.05).
Multivariable models
Ordinal logistic regression was used to model the relationship between clinical characteristics
and taxa found to be altered on LEfSe, with patients classified across 4 ranked quartiles of rela-
tive abundance of Cluster IV/XIVa Clostridia or Enterococcus from lowest to highest. Receipt
of antibiotics and anemia were significantly associated with decreased Cluster IV/XIVa
Fig 1. Changes within specific bacterial taxa, comparing ICU admission and 72 hours later. Using a linear discriminant analysis (LDA)-based algorithm,
significant declines were identified in the short chain fatty acid-producing Clostridial Clusters IV (Faecalibacterium prausnitzii) and XIVa (Blautia,
Coprococcus, Roseburia, and Ruminococcus) with an expansion in Enterococcus. Changes within specific bacterial taxa are shown as (A) LDA scores, which are
proportional to the relative change within each of the bacterial taxa shown, (B) a cladogram, which shows the hierarchical relationship of these different taxa in
relationship each other, and (C) relative abundance of these taxa. For (C) only taxa with a pooled minimum of 0.05% median relative abundance are depicted.
https://doi.org/10.1371/journal.pone.0200322.g001
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Clostridia (Table 2). Assessing for dynamic changes, the development of new fever was also
associated with decreased Cluster IV/XIVa Clostridia after 72 hours and was included in the
final model. When diversity (Shannon index) was added to the final model as a linear variable,
the relationship between receipt of antibiotics and Cluster IV/XIVa Clostridia lost significance
(OR 2.15, 95% CI 0.77–6.04). When patients with documented gastrointestinal bleeding were
excluded, there was no change in the relationship between anemia and levels of Cluster IV/
XIVa Clostridia (OR 3.93, 95% CI 1.37–11.3). None of the model estimates were altered by
adjusting for acute severity of illness. Clinical characteristics were examined in relationship to
the relative abundance of Enterococcus after 72 hours and only receipt of antibiotics was signif-
icantly associated with increased Enterococcus (Table 3).
In addition to the above approach using quartiles, linear regression analysis was performed
with the relative abundance for Enterococcus and Clostridial Clusters IV/XIVa classified as
continuous, log-transformed linear measures. These results were qualitatively similar although
Fig 2. Principal coordinates analysis (PCoA) of subjects at time of ICU admission (A) and 72 hours later (B), stratified by relative abundance Clostridial
Clusters IV and XIVa. There was distinct clustering of subjects based on levels of Clostridial Clusters IV and XIVa both at ICU admission and 72 hours later even
though these Clostridia made up<1% overall relative abundance of the fecal microbiome. Taxa included in Cluster IV/XIVa: F. prausnitzii, Blautia, Coprococcus,
Roseburia, and Ruminococcus. Subjects are color-coded by pooled levels of Cluster IV/XIVa Clostridia, from the lowest relative abundance (Quartile 1) to the highest
relative abundance (Quartile 4).
https://doi.org/10.1371/journal.pone.0200322.g002
Fig 3. Relationship between Clostridial Clusters IV and XIVa and gut microbiome diversity and stability. Lower levels of Clostridial Clusters IV
and XIVa at 72 hours were associated with decreased fecal biodiversity at 72 hours (A) and with decreased community stability over time (B). To test
for a relationship between Cluster IV/XIVa Clostridia and fecal biodiversity, Shannon index was calculated for each sample and compared across
levels of these taxa. To test for a relationship between Cluster IV/XIVa Clostridia and community stability, unweighted UniFrac distance was
calculated for each subject comparing ICU admission to 72 hours later and compared across levels of these Clusters.
https://doi.org/10.1371/journal.pone.0200322.g003
Loss of Clostridial Clusters IV and XIVa in the ICU
PLOS ONE | https://doi.org/10.1371/journal.pone.0200322 August 1, 2018 7 / 16
effect size estimates increased. After adjusting for other clinical variables, antibiotics were
again the most important risk factor associated with increased relative abundance of Enterococ-
cus (OR 5.81, 95% CI 1.17–28.7) and with decreased relative abundance of Clostridial Clusters
IV/XIVa (OR 8.01, 95% CI 1.71–36.6).
Discussion
In this prospective cohort study, initial treatment in the ICU was accompanied by a rapid loss
of short chain fatty acid (SCFA)-producing bacteria within Clostridial Clusters IV (Faecalibac-
terium prausnitzii) and XIVa (Blautia, Coprococcus, Roseburia, and Ruminococcus) [30]. Loss
of these SCFA-producing Clostridia was associated with low overall bacterial biodiversity, with
evidence of community instability and with an expansion in Enterococcus (including VRE).
These data suggest that loss of Cluster IV/XIVa Clostridia in the ICU may be associated with
deleterious changes within the structure of the fecal microbiome and these bacteria may be
good candidates for further study in the critical care setting, especially studies seeking to deter-
mine if these candidate species can predict adverse outcomes in the ICU.
SCFA-producing Clostridial Clusters were identified based on an untargeted analysis dem-
onstrating within-individual loss of these taxa with a concurrent rise in Enterococcus (includ-
ing VRE). These findings are consistent with prior studies which demonstrate the importance
of these organisms for maintenance of gut homeostasis [13] and extend this finding into the
ICU setting. In a recent prior study comparing the fecal microbiome of 10 ICU patients to
healthy subjects, there was a decreased abundance of Clostridia clusters IV/XIa and increased
abundance of Enterococcus [31]. In another cohort of 34 ICU patients, there was a lower abun-
dance of Faecalibacterium, Ruminococus and Blautia, all taxa in Clostridia clusters IV/XIV,
compared to healthy subjects [32]. The current study extends these findings to a larger ICU
cohort, and assesses dynamic changes within these taxa. Recent data also support the idea that
SCFA producers are important in colonization resistance against VRE. Specifically, butyrate
producing bacteria may restrict the outgrowth of potential pathogens through intracellular
butyrate sensor peroxisome proliferator-activated receptor γ (PPAR-γ) and by limiting
Fig 4. Fecal microbial diversity and Enterococcus after 72 hours in the intensive care unit (ICU). Higher levels of
Enterococcus were associated with decreased fecal biodiversity (Shannon Index).
https://doi.org/10.1371/journal.pone.0200322.g004
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luminal oxygen [33]. Cluster XIVa Clostridia (Blautia producta and Clostridium Bolteae) pre-
vents VRE colonization in antibiotic-treated mice and inhibition of VRE colonization seems
to be the result of a direct interaction between B. producta and VRE [34]. In BMT patients, low
fecal microbial diversity at the time of BMT predicted VRE bacteremia and mortality [8, 9, 35].
In the ICU, prolonged stays have been associated with a progressive loss of Clostridia with
replacement by Enterococcus [7] and low fecal SCFA levels have been correlated with domina-
tion by Enterococcus and with worse clinical outcomes [14, 36]. Our study highlights the
potential importance of SCFA producers in preventing VRE colonization in an ICU-based
population.
In addition to VRE, we found inverse relationships between Cluster IV/XIVa Clostridia
and other potential pathogens including Staphylococcus and Enterobacteriaceae. Prior studies
support the hypothesis that SCFA producers have a role in gut microbiome homeostasis that
extends beyond colonization resistance against VRE [37]. SCFAs are produced from dietary
fiber and have been linked to decreased colonic inflammation [38], an enlarged pool of regula-
tory T cells [39], and beneficial effects on energy metabolism [40]. In animals, fiber deprivation
led to thinning of the colonic mucus layer and increased pathogen susceptibility [41]. In BMT
Table 2. Relationship between clinical variables and decreased Clostridial Clusters IV and XIVa after 72 hours in
the ICU.
Variable Unadjusted
OR (95% CI) 
Multivariable
OR (95% CI) 
Demographics
Female sex 1.17 (0.57–2.43) —
Age
<60 years old Ref Ref
60–68 years old 0.60 (0.24–1.46) —
>68 years old 0.82 (0.33–2.04) —
Surgical admission 1.29 (0.62–2.72) —
Clinical characteristics after 72 hours
Fever (temp >38˚C)
Newly developing 2.84 (0.60–13.6) 5.07 (1.02–25.2)
After 72 hours 2.61 (0.65–10.5) —
Hematocrit <33.8% 5.36 (2.11–13.6) 5.08 (1.77–14.6)
WBC12,000 x 109/L 0.96 (0.46–2.01) —
Albumin <3.5 g/dL 2.18 (1.00–4.76) 1.07 (0.44–2.60)
APACHE IV score 1.00 (0.99–1.02) —
Treatment-related characteristics over 72 hours
Antibiotics (any) 3.86 (1.47–10.1) 2.90 (1.06–7.91)
PPIs (any) 1.92 (0.91–4.02) —
Ventilation72 Hours 1.28 (0.51–3.26) —
Hemodialysis 1.53 (0.41–5.76) —
Enteral feeding 0.89 (0.37–2.15) —
ICU: intensive care unit; OR: odds ratio; CI: confidence interval; WBC: white blood cell count; APACHE: acute
physiology and chronic health evaluation. Shown are patient characteristics that significantly changed during the 72
hours after ICU admission and all treatment-related variables. Boldfaced variables were significant at p<0.05 in the
final model.
Ordinal logistic regression: ORs represent odds of moving from a higher into a lower quartile of relative abundance
of Clostridial Clusters IV and XIVa.
Comparator: medical admission.
https://doi.org/10.1371/journal.pone.0200322.t002
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patients, taxa within Cluster IV/XIVa Clostridia were associated with decreased risk for Clos-
tridium difficile infection [42]. In ICU patients sampled within 48 hours of admission and at
ICU discharge, loss of Faecalibacterium was associated with loss of diversity and outgrowth of
Enterobacteriaceae [15, 43]. In our data, Cluster IV/XIVa Clostridia comprised a small propor-
tion of the total gut microbiome by abundance yet explained a large degree of inter-individual
variability on clustering analyses and were highly correlated with diversity and community sta-
bility, typical markers for a healthy gut microbiome across populations [44, 45]. These findings
imply that these bacteria may serve a critical functional role in the distal gut. Yet fiber, the pri-
mary fuel substrate for the Clostridia identified here, is often missing from the enteral feeds
used in the ICU [46].
In this data, receipt of antibiotics was associated with low levels of Cluster IV/XIVa Clos-
tridia and with high levels of Enterococcus. Subjects who received antibiotics had increased lev-
els of Enterococcus on sequencing, and subjects who received vancomycin had a 15% absolute
increase in rates of VRE colonization based on culture. Approximately 75% of ICU patients
receive antibiotics for known or suspected infections [47, 48] and, often broad-spectrum anti-
biotics are given before the results of cultures or other testing become available. Our data






Female sex 1.05 (0.51–2.18) —
Age
<60 years old Ref Ref
60–68 years old 0.78 (0.32–1.88) —
>68 years old 0.88 (0.36–2.16) —
Surgical admission 0.50 (0.23–1.06) —
Clinical characteristics after 72 hours
Fever (temp >38˚C)
Newly developing 0.48 (0.12–1.98) —
After 72 hours 0.51 (0.10–2.54) —
Hematocrit <33.8% 1.65 (0.72–3.81) —
WBC12,000 x 109/L 1.30 (0.61–2.75) —
Albumin <3.5 g/dL 1.24 (0.59–2.61) —
APACHE IV score 1.02 (1.00–1.03) 1.00 (0.98–1.02)
Treatment-related characteristics over 72 hours
Antibiotics (any) 3.19 (1.33–7.67) 2.66 (1.08–6.57)
PPIs (any) 0.69 (0.33–1.44) —
Ventilation72 Hours 3.51 (1.26–9.79) 1.49 (0.32–6.94)
Hemodialysis 1.03 (0.21–4.99) —
Enteral feeding 0.31 (0.12–0.79) 0.40 (0.15–1.11)
ICU: intensive care unit; OR: odds ratio; CI: confidence interval; WBC: white blood cell count; APACHE: acute
physiology and chronic health evaluation. Shown are patient characteristics that significantly changed during the 72
hours after ICU admission and all treatment-related variables. Boldfaced variables were significant at p<0.05 in the
final model.
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support the idea that antibiotics induce broad structural changes within the gut microbiome
and is consistent with the observation that antibiotics promote colonization with antibiotic-
resistant bacteria [49]. However, allocation of antibiotics was not random, and it is also possi-
ble that unidentified patient characteristics determined both use of antibiotics and the micro-
biome changes that we observed.
There is substantial interest in testing pre- or probiotics to prevent infections in the ICU. In
murine models, defined mixtures of bacteria including bacteria within the Clostridial Clusters
IV/XIVa provided colonization resistance to VRE after antibiotic challenge [50] and promoted
VRE intestinal clearance [34]. In germ-free mice, a consortium of Clostridia including Clusters
IV/XIVa conferred colonization resistance to the enteric pathogens S. Typhimurium and C.
rodentium [51]. In a murine sepsis model, there was a survival benefit with fiber supplementa-
tion, mediated in part by a rise in Cluster XIVa Clostridia [52]. To date, clinical trials testing
probiotics have delivered heterogeneous organisms (e.g., Lactobacillus or Bifidobacterium sp.)
and have had mixed results or in some cases have been associated with harm [53–55]. Future
studies may wish to address whether SCFA-producing Clostridia, or related prebiotics, can be
successfully delivered and retained within the colonic microbiome.
Our study has several strengths. There was a rigorous protocol for sample collection,
with subjects sampled immediately at the time of ICU admission and again 72 hours later.
This serial sampling permitted evaluation for dynamic within-individual changes over the
initial ICU treatment period. A broad swath of clinical data was ascertained both at ICU
admission and 72 hours later, which allowed us to assess relationships after adjusting for
underlying patient factors. Standard bacterial culture for VRE was used to confirm
sequencing results related to Enterococcus, the main pathogen showing outgrowth in these
subjects.
There are also limitations. Because we sought to acquire samples immediately at the time
of ICU admission, it was not possible to gather whole stools and therefore not possible to
directly assay levels of SCFAs. Despite this early acquisition of samples, potentially protec-
tive bacterial taxa may be lost prior to ICU admission and potentially pathogenic bacteria
may be gained [56]. Our approach focused on ICU admission and 72 hours later because by
72 hours the clinical outcomes of most patients are determined [57]. This study was con-
ducted in multiple ICUs within a single tertiary care center and the prevalence of specific
organisms and antibiotic susceptibilities is likely to differ at other institutions. Finally, our
conclusions should be tempered by recognizing that there is a dense network of interdepen-
dency between gut commensals [58]. No single bacterial species, and probably no single
functionally related group of bacteria, is likely to be completely responsible for colonization
resistance.
In summary, we found that Clostridia within the Clusters IV/XIVa were rapidly lost during
the initial treatment period in the ICU. Low levels of Cluster IV/XIVa Clostridia were associ-
ated with receipt of antibiotics, but no other potentially modifiable ICU interventions. Low
levels of Cluster IV/XIVa Clostridia were also associated with low fecal microbial diversity,
microbiome community instability, and the outgrowth of VRE. SCFA-producing Clostridia
may serve a role in the maintenance of normal gastrointestinal colonization resistance in the
ICU.
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